Premium
Current status of the therapy of advanced renal carcinoma
Author(s) -
Hrushesky William J.,
Murphy Gerald P.
Publication year - 1977
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930090310
Subject(s) - medicine , vinblastine , chemotherapy , immunotherapy , adjuvant , oncology , renal cell carcinoma , hormone , intensive care medicine , cancer
A preclinical murine renal tumor model system is available for evaluation of the effectiveness of therapeutic agents. Clinical review reveals that objective response rates to hormonal agents reported since 1971 have been substantially lower than those reported prior to 1971. Many chemotherapeutic agents have not been adequately evaluated clinically or with the experimental model. Vinblastine to date may be the most active single agent with a 25% objective response rate. At the present time, it is uncertain whether combination chemotherapy or hormonal chemotherapy add to response rates obtained with single agents. There is some evidence that immunotherapy may be of some adjuvant benefit and, thus, may provide an additional avenue of investigation.